Biochemical and biophysical research communications · 2026
Network pharmacology-guided identification and validation of ganoderic acids A and D from Ganoderma lucidum against esophageal squamous cell carcinoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Yu, Xie Yinchun, Meng Shishi, Huang Jiaqi, Hu Huijing, Wu Meiqi, Chen Qiaoli, Wu Peifeng, Li Jianglin, Wang Shaoxiang, He Gang, Wang Shaoqi, Wang Xiao
Аннотация
BACKGROUND/OBJECTIVE: Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with unsatisfactory prognosis and ongoing therapeutic challenges. Ganoderma lucidum has been widely investigated for anticancer activity, but the specific monomeric ganoderic acids that may contribute to anti-ESCC effects and their potential target context remain insufficiently characterized.
METHODS: Compounds and targets were prioritized through network pharmacology, ADME evaluation, disease-target integration and TCGA-based clinical bioinformatics. Molecular docking and 100-ns molecular dynamics (MD) simulations were used to evaluate putative ligand-target binding stability. The effects of ganoderic acid A (GA-A) and ganoderic acid D (GA-D) were assessed in ESCC and normal esophageal epithelial cells using image-based cell counting, EdU incorporation assays, flow cytometric cell-cycle and apoptosis analyses, and immunoblotting of mTORC1-associated readouts.
RESULTS: Nine compounds and 191 drug-disease intersection targets were identified. GA-A and GA-D were prioritized as core ganoderic acid monomers based on network connectivity, pharmacological relevance and experimental feasibility. Enrichment analysis implicated cancer-related signaling, including PI3K-Akt/mTOR-associated pathways. Docking and MD simulations supported stable putative interactions between GA-A/GA-D and mTOR. In vitro, both compounds reduced cell number and EdU incorporation in ECSS cells, and induced G0/G1 accumulation and apoptosis, with GA-D showing stronger anti-proliferative activity than GA-A under the tested conditions. HEEC cells were less sensitive under the tested conditions. GA-A and GA-D also reduced phosphorylated S6 and 4EBP1 levels.
CONCLUSION: This study identifies GA-A and GA-D, particularly GA-D, as candidate anti-proliferative monomers from G. lucidum against ESCC. The findings provide a focused, experimentally supported basis for further mechanistic evaluation of ganoderic acids, including target engagement assays and drug-treated transcriptomic profiling.
METHODS: Compounds and targets were prioritized through network pharmacology, ADME evaluation, disease-target integration and TCGA-based clinical bioinformatics. Molecular docking and 100-ns molecular dynamics (MD) simulations were used to evaluate putative ligand-target binding stability. The effects of ganoderic acid A (GA-A) and ganoderic acid D (GA-D) were assessed in ESCC and normal esophageal epithelial cells using image-based cell counting, EdU incorporation assays, flow cytometric cell-cycle and apoptosis analyses, and immunoblotting of mTORC1-associated readouts.
RESULTS: Nine compounds and 191 drug-disease intersection targets were identified. GA-A and GA-D were prioritized as core ganoderic acid monomers based on network connectivity, pharmacological relevance and experimental feasibility. Enrichment analysis implicated cancer-related signaling, including PI3K-Akt/mTOR-associated pathways. Docking and MD simulations supported stable putative interactions between GA-A/GA-D and mTOR. In vitro, both compounds reduced cell number and EdU incorporation in ECSS cells, and induced G0/G1 accumulation and apoptosis, with GA-D showing stronger anti-proliferative activity than GA-A under the tested conditions. HEEC cells were less sensitive under the tested conditions. GA-A and GA-D also reduced phosphorylated S6 and 4EBP1 levels.
CONCLUSION: This study identifies GA-A and GA-D, particularly GA-D, as candidate anti-proliferative monomers from G. lucidum against ESCC. The findings provide a focused, experimentally supported basis for further mechanistic evaluation of ganoderic acids, including target engagement assays and drug-treated transcriptomic profiling.